US Tardive Dyskinesia Treatment Market - 2024-2031

September 2024 | 57 pages | ID: U2B78A904293EN
DataM Intelligence

Abstracts

US Tardive Dyskinesia Treatment Market reached US$ 3061.64 million in 2023 and is expected to reach US$ 6417.43 million by 2031, growing with a CAGR of 9.80% during the forecast period 2026-2031.

The US Tardive Dyskinesia Treatment Market emerges as a key focus in DataM Intelligence latest in-depth analysis, where seasoned researchers harness advanced data analytics and strategic foresight to deliver unparalleled market intelligence. This insightful report meticulously explores the competitive landscape, profiling key players and their forward-thinking innovations in product development, pricing strategies, financial metrics, and global expansion initiatives. By uncovering the driving forces, market dynamics, and disruptive trends shaping the future, this research equips industry stakeholders with the actionable insights needed to make informed decisions in an increasingly dynamic and competitive environment.

A US Tardive Dyskinesia Treatment Market is a data-driven software solution that collects, integrates, analyzes, and visualizes customer data across various touchpoints to generate actionable insights. These platforms help businesses understand customer behaviors, preferences, and purchasing patterns in real time, enabling personalized marketing, enhanced customer engagement, and data-driven decision-making.

By Drug

• Valbenazine*
• Tetrabenazine
• Deutetrabenazine
• Amantadine
• Clonazepam
• Others

By Distribution Channel

By End-User

This Report Covers:

• Go-to-market Strategy.
• Neutral perspective on the market performance.
• Development trends, competitive landscape analysis, supply side analysis, demand side analysis, year-on-year growth, competitive benchmarking, vendor identification, and other significant analysis, as well as development status.
• Customized regional/country reports as per request and country level analysis.
• Potential & niche segments and regions exhibiting promising growth covered.
• Analysis of Market Size (historical and forecast), Total Addressable Market (TAM), Serviceable Available Market (SAM), Serviceable Obtainable Market (SOM), Market Growth, Technological Trends, Market Share, Market Dynamics, Competitive Landscape and Major Players (Innovators, Start-ups, Laggard, and Pioneer).

Research Process:

Both primary and secondary data sources have been used in the global US Tardive Dyskinesia Treatment Market research report. During the research process, a wide range of industry-affecting factors are examined, including governmental regulations, market conditions, competitive levels, historical data, market situation, technological advancements, upcoming developments, in related businesses, as well as market volatility, prospects, potential barriers, and challenges.

Contents

1. U.S. TARDIVE DYSKINESIA TREATMENT MARKET – METHODOLOGY AND SCOPE

1.1. Research Methodology
1.2. Scope of the Report

2. U.S. TARDIVE DYSKINESIA TREATMENT MARKET – DEFINITION AND OVERVIEW

3. U.S. TARDIVE DYSKINESIA TREATMENT MARKET – EXECUTIVE SUMMARY

3.1. Market Snippet by Drug
3.2. Market Snippet by Distribution Channel
3.3. Market Snippet by Region

4. U.S. TARDIVE DYSKINESIA TREATMENT MARKET – MARKET DYNAMICS

4.1. Market Drivers
  4.1.1. Increasing clinical approvals
  4.1.2. Prolonged use of antipsychotic drugs by patients
  4.1.3. An increase in the aging population
4.2. Market Restraints
  4.2.1. Side effects associated with the drugs
  4.2.2. Lack of awareness about the disorder
4.3. Market Opportunity
4.4. Emerging Countries
4.5. The development of novel therapies
4.6. Impact Analysis

5. U.S. TARDIVE DYSKINESIA TREATMENT MARKET – INDUSTRY FACTORS

5.1. Porter’s Five Force Analysis
5.2. Regulatory Analysis
5.3. Supply Chain Analysis
5.4. Pricing Analysis
5.5. Patent Analysis
5.6. SWOT Analysis
5.7. Unmet Needs
5.8. Epidemiology Analysis

6. U.S. TARDIVE DYSKINESIA TREATMENT MARKET – COVID-19

6.1. Analysis of COVID-19 on the Market*
  6.1.1. Scenario Before COVID
  6.1.2. Scenario During COVID
  6.1.3. Scenario After COVID
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During Pandemic
6.5. Manufacturers Strategic Initiatives
6.6. Conclusion

7. U.S. TARDIVE DYSKINESIA TREATMENT MARKET – BY DRUG

7.1. Introduction
  7.1.1. Market Size and Y-o-Y Growth Analysis (%), By Drug
  7.1.2. Market Attractiveness Index, By Drug
7.2. Valbenazine*
  7.2.1. Introduction
  7.2.2. Market Size, 2022-2031 and Y-o-Y Growth (%), 2023-2031
7.3. Tetrabenazine
7.4. Deutetrabenazine
7.5. Amantadine
7.6. Clonazepam
7.7. Others

8. U.S. TARDIVE DYSKINESIA TREATMENT MARKET – BY DISTRIBUTION CHANNEL

8.1. Introduction
  8.1.1. Market Size and Y-o-Y Growth Analysis (%), By End-User
  8.1.2. Market Attractiveness Index, By End-User

9. HOSPITAL AND SPECIALITY PHARMACIES*

9.1. Introduction
9.2. Market Size, 2022-2031 and Y-o-Y Growth (%), 2023-2031

10. RETAIL PHARMACIES

11. OTHERS

12. U.S. TARDIVE DYSKINESIA TREATMENT MARKET – COMPETITIVE LANDSCAPE

12.1. Competitive Scenario
12.2. Market Positioning/Share Analysis
12.3. Mergers and Acquisitions Analysis

13. U.S. TARDIVE DYSKINESIA TREATMENT MARKET – COMPANY PROFILES

13.1. Teva Pharmaceutical Industries Ltd*
  13.1.1. Company Overview
  13.1.2. Product Portfolio and Description
  13.1.3. Key Highlights
  13.1.4. Financial Overview
13.2. Neurocrine Biosciences, Inc.
13.3. Lupin Limited
13.4. Accord Healthcare, Inc.
13.5. Mitsubishi Corporation
13.6. Dr. Reddy’s Laboratories Limited
13.7. BIONPHARMA INC.
13.8. Slate Run Pharmaceuticals
13.9. Aurobindo Pharma Limited
13.10. Apotex Inc.

14. U.S. TARDIVE DYSKINESIA TREATMENT MARKET – DATAM

14.1. Appendix
14.2. About Us and Services
14.3. Contact Us